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Abstract
Sepsis is a severe and life-threatening systemic inflammatory response to infection that affects all populations and
age groups. The pathophysiology of sepsis is associated with aberrant interaction between leukocytes and the vascular
endothelium. As inflammation progresses, the adhesion molecules that mediate these interactions become shed from
cell surfaces and accumulate in the blood as soluble isoforms that are being explored as potential prognostic disease
biomarkers. We critically review the studies that have tested the predictive value of soluble adhesion molecules in
sepsis pathophysiology with emphasis on age, as well as the underlying mechanisms and potential roles for inflammatory
shedding. Five soluble adhesion molecules are associated with sepsis, specifically, E-selectin, L-selectin and P-selectin,
intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. While increased levels of these soluble
adhesion molecules generally correlate well with the presence of sepsis, their degree of elevation is still poorly
predictive of sepsis severity scores, outcome and mortality. Separate analyses of neonates, children and adults
demonstrate significant age-dependent discrepancies in both basal and septic levels of circulating soluble adhesion
molecules. Additionally, a range of both clinical and experimental studies suggests protective roles for adhesion
molecule shedding that raise important questions about whether these should positively or negatively correlate
with mortality. In conclusion, while predictive properties of soluble adhesion molecules have been researched
intensively, their levels are still poorly predictive of sepsis outcome and mortality. We propose two novel directions
for improving clinical utility of soluble adhesion molecules: the combined simultaneous analysis of levels of adhesion
molecules and their sheddases; and taking age-related discrepancies into account. Further attention to these issues
may provide better understanding of sepsis pathophysiology and increase the usefulness of soluble adhesion
molecules as diagnostic and predictive biomarkers.
Introduction
Sepsis [1], due to its detrimental sequelae and limited
therapeutic options, continues to be responsible for many
deaths amongst all age groups [2-4]. Growing evidence in-
dicates that aberrant leukocyte activation and recruitment
into host tissues plays a pivotal role in causing breakdown
of the vascular endothelium [5], which in turn leads to
organ failure and death [6]. Inflammatory leukocyte recruit-
ment is initiated by soluble mediators (for example, cyto-
kines or bacterial-derived lipopolysaccharide (endotoxin)),
which upregulate adhesion molecule expression on both
leukocytes and the endothelium. This upregulation results
in a multistep adhesion cascade whereby circulating im-
mune cells sequentially roll on, firmly adhere to, and
transmigrate across the endothelium [7-9]. During the
progression of inflammatory responses, soluble iso-
forms of the leukocyte recruitment adhesion molecules
are shed from cell surfaces and accumulate within the
circulating blood plasma [10]. These soluble isoforms
have been considered promising prognostic biomarkers
of severity of inflammation but the clinical utility of
monitoring such changes remains poor [11].
One reason for the thus far limited clinical utility of
these soluble isoforms is the fact that shedding in
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quence of upregulated expression/cell activation. Most
shedding is an active process, which is discretely regu-
lated by diverse proteolytic enzymes, although cell dam-
age can also variably contribute to soluble adhesion
molecule levels [10]. Although still a matter of contro-
versy, there is increasing evidence that shedding serves
regulatory roles to dampen inflammation (and specific-
ally to reduce leukocyte–endothelial interactions) and
protect the host from excessive collateral damage [10,12].
Furthermore, age-related differences in both levels of
soluble adhesion molecules and the enzymes that me-
diate shedding have been observed in both healthy and
septic patients (as discussed in detail below). The rela-
tionship between soluble adhesion molecule levels,
underlying inflammatory and shedding activities and
clinical outcomes may thus be more complex than
once thought.
The goals of this review are therefore to summarize
existing knowledge regarding the mechanisms and putative
functions for shedding of cell surface adhesion molecules/
generation of soluble isoforms, unequivocally identified to
exist at elevated levels in the blood of septic patients, and
to investigate how these levels and their shedding differ
amongst healthy and septic neonates, children and adults
to improve our understanding and clinical utility of soluble
adhesion molecules.
Literature search
We performed a comprehensive literature search in MED-
LINE using medical subject headings and text words, sup-
plemented by scanning the bibliographies of the recovered
articles. We combined ‘endothelium’ and ‘leukocytes’
using the term ‘OR’. This search was subsequently com-
bined with ‘sepsis’ using the Boolean operator ‘AND’.W e
used a similar search strategy, using the terms ‘soluble’
and ‘circulating adhesion molecules’. We combined these
results with the terms ‘sepsis’, ‘septic shock’, ‘endothelium’,
‘leukocytes’, ‘monocytes’, ‘granulocytes’, ‘macrophages’,
‘neutrophils’, ‘lymphocytes’ and ‘inflammation’.W et h e n
combined these results with the terms ‘children’,‘neonates’,
‘adults’ and ‘age’.
Soluble adhesion molecules: from cell surface to
circulation
Five soluble adhesion molecules were associated with
sepsis and their main characteristics are summarized in
Table 1. Three adhesion molecules (E-selectin, L-selectin
and P-selectin) belong to the selectin superfamily and
function in leukocyte rolling (Figure 1). Two adhesion
molecules (intercellular adhesion molecule 1 (ICAM-1)
and vascular cell adhesion molecule 1 (VCAM-1)) be-
long to the immunoglobin domain superfamily cell ad-
hesion molecules that are important for firm adhesion
and transendothelial migration [13]. In all cases, inflam-
matory mediators (for example, cytokines, thrombin,
lipopolysaccharide) first increase cell surface expression
of these molecules followed by the later appearance of
shed, soluble isoforms (Table 1 and Figure 2).
E-selectin
Soluble isoforms of E-selectin can be found in the super-
natant of endothelial cells cultured in vitro within 24
hours of cytokine activation and are generated through a
largely caspase-dependent shedding process [10,14-16].
In healthy individuals low levels of soluble E-selectin
(sE-selectin) are found in serum, but these levels are
greatly elevated in septic patients [16,17]. Importantly,
shed sE-selectin from sera of septic patients retained the
ability to adhere to granulocytes in vitro [16]. Shedding
of E-selectin has thus been proposed to limit leukocyte–
endothelial interactions both by decreasing the cell sur-
face density on the endothelium and by generating an
intravascular competitive inhibitor or decoy ligand (that
is, sE-selectin) for leukocytes, thereby reducing collateral
damage in the host [18]. Indeed, one clinical study found
that while sE-selectin was elevated in septic children,
those with the highest levels exhibited the best outcomes
and survival rates [19].
Table 1 Characteristics of adhesion molecules involved in sepsis
Adhesion
molecule
Expression Ligands Inflammatory mediators Mode of expression Specific function Sheddase
E-selectin Endothelial cells ESLG-1, PSGL-1 TNFα, LPS, IL-1 Inducible Rolling Caspase
L-selectin Leukocytes GlyCAM-1, MAdCAM-1 TNFα, LPS, IL-1, IL-6 Constitutive, inducible Rolling ADAM-17
P-selectin Endothelial cells,
platelets
PSGL-1 TNFα, IL-4, IL-13, histamine,
thrombin
Constitutive Rolling MMP
ICAM-1 Endothelial cells Mac-1, LFA-1 TNFα, LPS, IL-1 Constitutive, inducible Firm adhesion, TEM ADAM-17, NE
VCAM-1 Endothelial cells VLA-4 TNFα, LPS, IL-1 Constitutive, inducible Firm adhesion, TEM ADAM-17, NE
ADAM, a disintegrin and metalloproteinase; ESGL-1, endothelial selectin glycoprotein ligand; GlyCAM-1, glycosylation dependent cell adhesion molecule; ICAM-1,
intercellular adhesion molecule-1; IL, interleukin; LFA, leukocyte function antigen; LPS, lipopolysaccharide; Mac, macrophage antigen; MAdCAM, mucosal vascular
addressin cell adhesion molecule; MMP, matrix metalloproteinase; NE, neutrophil elastase; PSGL, platelet selectin glycoprotein ligand; TEM, transendothelial
migration; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule-1; VLA,v e r yl a t ea n t i g e n .
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Within approximately 10 to 15 minutes of leukocyte activa-
tion by cytokines (for example, tumor necrosis factor alpha)
or lipopolysaccharide, soluble L-selectin (sL-selectin) is
m e a s u r a b l ei nt h eb l o o dp l a s m aa sar e s u l to fc l e a v a g eb ya
disintegrin and metalloproteinase (ADAM)-17 [10,20,21].
Clinical studies show that L-selectin is shed and detected at
elevated levels in the plasma during the systemic inflamma-
tory response [22]. Interestingly, Seidelin and colleagues
[22] found that the greatest survival was among septic
adults that presented with the highest levels of sL-selectin,
and similar findings were made in another study focused
on children [19]. Additionally, in an in vitro fluid shear flow
model, exogenously added sL-selectin inhibited leukocyte
rolling and firm adhesion to the endothelium in a dose-
dependent manner, presumably by competing with cell sur-
face L-selectin for binding of endothelial ligands [23].
Moreover, Ferri and colleagues have demonstrated that sys-
temic administration of exogenous sL-selectin to mice
in vivo reduced intravascular leukocyte rolling and adhe-
sion, and as a consequence decreased vascular leak in
models of both local inflammation and sepsis [24-26].
Alternatively, addition of a small molecule inhibitor of
shedding increased leukocyte adhesion and vascular leak in
the same settings [26]. The authors thus propose a signifi-
cant protective role for L-selectin shedding in sepsis.
P-selectin
P-selectin is found within both endothelial cells and
platelets [27,28]. As with the other selectins, P-selectin
can be measured in its soluble form in cell culture su-
pernatants and in blood plasma, with greater levels
found in septic patient plasma [29]. Mechanisms for
P-selectin shedding remain poorly characterized, al-
though some experimental data show that shedding of
P-selectin might occur through cleavage by matrix me-
talloproteinase in patients with cardiovascular disease
or hypertension [30,31]. The degree to which plasma
soluble P-selectin (sP-selectin) is derived from endo-
thelial cells versus platelets remains unclear. However,
one study found a strong positive correlation between
coagulation (disseminated intravascular coagulation,
fibrinogen consumption and thrombin activation markers)
and sP-selectin in septic patients, indicating a significant
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Figure 1 Stages of extravasation of a leukocyte. (A) Leukocytes first undergo tethering and rolling on the endothelium, mediated by E-selectin,
L-selectin, and P-selectin and their carbohydrate ligands. Activation and adhesion: leukocyte rolling facilitates interaction with chemoattractants
present on endothelial surfaces, which in turn causes leukocyte activation that triggers firm adhesion and arrest, mediated by the integrins macrophage-1
(Mac-1), leukocyte function antigen-1 (LFA-1) and very late antigen-4 (VLA-4) binding to their endothelial ligands intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1). Subsequently, leukocytes engage in lateral migration over the endothelial wall in search of a
site to transmigrate, guided by VCAM-1/ICAM-1-enriched transmigratory cups (asterisks in (B) and (C)), present on endothelial cells. The last step
in this cascade is transendothelial migration or diapedesis, whereby the leukocytes cross the endothelial barrier, either (B) paracellular, through
the interendothelial junctions, or (C) transcellular, via the formation of a transcellular pore. See [7-9,13] for additional details.
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of its sources, sP-selectin could negatively modulate direct
leukocyte–endothelial interactions and/or indirect platelet-
mediated secondary capture of leukocytes on the endothe-
lium (both of which are dependent on P-selectin–platelet
selectin glycoprotein ligand-1 adhesion), although this re-
mains to be tested directly [28].
Intercellular adhesion molecule-1
In vitro 1 to 6 hours after activation of endothelial cells
by cytokines, soluble ICAM-1 (sICAM-1) can be mea-
sured in culture supernatants, after shedding mediated
by neutrophil elastase-dependent, ADAM-17-dependent
and matrix metalloproteinase-9-dependent shedding
[10,33-35]. Shedding of ICAM-1 is thought to promote
detachment of leukocytes from the endothelium, thus
limiting local inflammation [10]. Indeed, addition of
exogenous neutrophil elastase was shown to be highly
effective at cleaving surface-bound human ICAM-1
in vitro, which in turn abrogated Mac-1-dependent
leukocyte adhesion [36]. Evidence supports a poten-
tially protective role for ICAM-1 shedding during sepsis.
Elevated levels of sICAM-1 are well documented in
human sepsis [5,6,11], and studies performed in both
humans and mice demonstrate that this is induced
within ~4 hours of endotoxin challenge [37-39]. Sig-
nificantly, septic children with the highest levels of
sICAM-1 had better outcomes/survival rates [19], sug-
gesting that shedding and loss of cell surface ICAM-1
f r o mt h ee n d o t h e l i u mm a ys e r v eap r o t e c t i v ef u n c t i o n .
Interestingly, in a cecal ligation puncture model of sep-
sis, ICAM-1-knockout mice – whereby cell-surface
ICAM-1 is completely abolished – exhibited a signifi-
cant decrease in leukocyte tissue invasion, organ dam-
age and mortality compared with wild-type mice [37].
Vascular cell adhesion molecule-1
In vitro 1 to 6 hours after cytokine activation, VCAM-1
is measurable in its soluble form (sVCAM-1) in endo-
thelial cell supernatant through shedding mediated by
ADAM-17, cathepsin G and neutrophil elastase [10].
Singh and colleagues demonstrate that this may be
achieved, at least in part, through the cytokine-mediated
(that is, interleukin-1β-mediated and tumor necrosis
B   Mechanisms for reduced adhesion after shedding
A   Adhesion cascade
VLA-4
VCAM-1
only illustrating this
receptor-ligand pair) Rolling Activation & Adhesion
1. Decreased Cell Surface Density 2. Decoy Ligands
Lateral migration & Diapedesis
Sheddase
Figure 2 Shedding of selectin and immunoglobulin superfamily adhesion molecules and its functional implications. For simplification,
only one example receptor ligand pair (very late antigen-4 (VLA-4)/vascular cell adhesion molecule-1 (VCAM-1)) is illustrated. (A) Interactions of
cell surface integrin VLA-4, present on leukocytes, with endothelial cell surface VCAM-1 during different steps in the leukocyte adhesion cascade.
(B) Ectodomain shedding of cell surface VCAM-1 (thereby generating the soluble isoform sVCAM-1) by sheddases might reduce leukocyte
adhesion to the endothelium on two complementary levels: reduction of cell surface density of adhesion molecules (for example, decreased
endothelial cell surface VCAM-1, in this example); and binding of the resulting soluble isoforms to cell surface ligands (that is, binding of
sVCAM-1 to leukocyte cell surface VLA-4 in this example), thereby serving as competitive antagonists (or decoy ligands) for the remaining
cell-surface adhesion receptors. See [10] and the text for more details on functional implications of shedding.
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tor metalloproteinase-3, which they showed to function
as a tonic suppressor of ADAM-17-mediated VCAM-1
shedding [40]. In response to endotoxin, sVCAM-1 was
observed to be markedly elevated in mice [38] and
humans [39]. Furthermore, increased levels of sVCAM-1
are reported in human sepsis, and higher levels seem to
be associated with increased severity of disease and non-
survival [5,6]. Shedding of VCAM-1 is implicated to
counteract the pro-adhesive state of leukocytes to the
endothelium both by lowering endothelial receptor
density [10] and by forming sVCAM-1 to act as a
competitive inhibitor (or decoy receptor) of leukocyte
very late antigen-4 [40,41] (Figure 2). Interestingly, pred-
nisolone – a synthetic glucocorticoid shown to be bene-
ficial in the treatment of sepsis – was shown to enhance
sVCAM-1 levels, suggesting the intriguing possibility
that its mechanism of action may be at least partially re-
lated to potentiation of VCAM-1 shedding [39].
Levels of soluble adhesion molecules: impact of age
Neonates
Basal levels of all soluble adhesion molecules of healthy
neonates are comparable with (sICAM-1) or higher than
Table 2 Levels of soluble E-selectin in neonates, children and adults
Study (reference) Mean age Sepsis criteria Healthy (μg/ml)
a Number
of patients
(healthy)
Sepsis (μg/ml)
a Number
of patients
(sepsis)
Neonates
Dollner and colleagues [52] 0 to 7 days Clinical 91.4 (2 to 217.8) 24 151.7 (37 to 362.2) 18
Austgulen and colleagues [45] Pre/at term Clinical 134.1 (69.5 to 280) 168 187.7 (118.4 to 262.2) 24
Edgar and colleagues [57] 0 to 7 days Clinical 71 (51 to 118) 27 135 (94 to 192) 192
Giannaki and colleagues [47] At term Clinical 139± 48 40
Edgar and colleagues [55] At term Clinical 71 (51 to 118) 46 158 (94 to 207) 46
Children
Andrys and colleagues [60] 6 to 10 57.6 (36.7 to 152.2) 68
11 to 15 42.1 (29.9 to 114.1) 90
Paize and colleagues [61] 2 to 16 PRISM 100 (90 to 110) 40 230 (100 to 380) 20
Krueger and colleagues [62] 3.5 (0.2 to 16) ACCP/SCCM 68 (49 to 105) 22 131 (112 to 146) 22
Whalen and colleagues [63] 1 day to 17 years Criteria of Doughty
and colleagues
b
46±6 14 230 77
Nash and colleagues [64] 9 70 (35 to 121) 81
15 59 (25 to 119)
Briassoulis and colleagues [19] 6.5 (2.8) PRISM 161± 43 10 936± 399 10
Adults
Presterl and colleagues [65] 51 (30 to 67) APACHE II 48.9 (14.3 to 89.9) 20 130 (40 to 570) 20
Weigand and colleagues [66] 58.7 (4.4) ACCP/SCCM 29 (14.3 to 89.9) 7 85 14
Hynninen and colleagues [67] 49 (17.2) APACHE II 73 (62 to 89) 11
Knapp and colleagues [68] 51 (21 to 96) APACHE III 43.7±20.3 15 94.5±54 28
Osmanovic and colleagues [69] Adult 28.5±14.3 18 118± 84 9
Soderquist and colleagues [70] 71 (10 to 91) Unknown 48 (20 to 97) 15 80 (22 to 200) 41
Takala and colleagues [71] 44 to 59 (17 to 86) APACHE II 45 (10 to 100) Unknown 154 (61 to 394) 20
Geppert and colleagues [72] 59 (35 to 85) SIRS 42.8±19.4 7 96.2±47.3 27
De Pablo and colleagues [73] 61.2 (3.2) APACHE II 48 36 98 52
Kayal and colleagues [74] 57.2 (3.9) ACCP/SCCM 40.5±4.5 9 231± 41.8 25
Shapiro and colleagues [6] 57 (19) APACHE III 49 207 95 13
Andrys and colleagues [60] 46 54.3 (8.3 to 116.9) 68
Giannaki and colleagues [47] Adult 48±13 40
ACCP/SCCM, American college of chest physicians/society of critical care medicine; APACHE, acute physiology and chronic health evaluation; PRISM, pediatric risk of
mortality; SIRS, systemic inflammatory response syndrome.
aData presented as mean (range) or mean ± standard deviation.
bCriteria from [75]. Ages expressed in
years unless otherwise stated.
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children or adults (Tables 2, 3, 4, 5 and 6 and Figure 3).
Only the levels of sL-selectin are lower in neonates than
in children or adults. Importantly, in neonatal sepsis,
levels of all soluble molecules are increased, but both
the relative and absolute extent of increase is remarkably
lower compared with adults or children (Tables 2, 3, 4, 5
and 6 and Figure 3). This raises the important question
of whether neonates are less effective at shedding or less
avidly upregulate adhesion molecules in the first place.
Indeed, some studies have been conducted to directly ad-
dress this issue, which suggests contributions from both
of these mechanisms. Cell surface levels of L-selectin on
neutrophils and sL-selectin levels from cord blood were
both lower than the cell surface and the circulating form
of L-selectin found in adult blood [42-44]. Interestingly,
Table 3 Levels of soluble L-selectin in neonates, children and adults
Study (reference) Mean age Sepsis criteria Healthy (μg/ml)
a Number
of patients
(healthy)
Sepsis (μg/ml)
a Number
of patients
(sepsis)
Neonates
Figueras-Aloy and colleagues [49] 0 to 14 days SNAP-II 580 (523 to 717) 12 681 (541 to 757) 15
Kourtis and colleagues [50] 0 to 2 days Clinical 1,155 75 1,331 (1,123 to 1,427) 14
Giannaki and colleagues [47] At term 674±223 40
Rebuck and colleagues [43] At term 463 (338 to 557) 22
Koenig and colleagues [42] 0 to 7 days 324±24 10
Children
Kourtis and colleagues [59] Children 3,356 (2,818 to 3,894) 100
Briassoulis and colleagues [19] 6.5 (2.8) PRISM 3,750±321 10 6,263± 3,813 10
Adults
Weigand and colleagues [66] 58.7 (4.4) ACCP/SCCM 460 7 400 14
Kourtis and colleagues [50] Adult 950 (700 to 1,220) 75
Schleiffenbaum and colleagues [23] Adult 1,600±800 63
Giannaki and colleagues [47] Adult 938±181 40
Rebuck and colleagues [43] Adult 717 (410 to 822) 22
Koenig and colleagues [42] Adult 537±28 9
ACCP/SCCM, American college of chest physicians/society of critical care medicine; PRISM, pediatric risk of mortality; SNAP, score for neonatal acute physiology.
aData presented as mean (range) or mean ± standard deviation. Ages expressed in years unless otherwise stated.
Table 4 Levels of soluble P-selectin in neonates, children and adults
Study (reference) Mean age Sepsis criteria Healthy (μg/ml)
a Number
of patients
(healthy)
Sepsis (μg/ml)
a Number
of patients
(sepsis)
Neonates
Figueras-Aloy and colleagues [49] 0 to 14 days SNAP-II 272 (152 to 288) 12 244 (170 to 324) 15
Sitaru and colleagues [48] 0 days Clinical 104± 71 10 222±128 9
Children
Paize and colleagues [61] 2 to 16 PRISM 50 (44 to 60) 40 61 (47 to 119) 20
Adults
Mosad and colleagues [32] 3 SIRS/SOFA 28.6±6 63± 9 176
Fijnheer and colleagues [29] Adult SIRS 122± 38 10 398±203 26
Weigand and colleagues [66] 58.7 (4.4) ACCP/SCCM 32.1±5.1 7 296 ±56 14
Osmanovic and colleagues [69] Adult Unknown 181± 44 18 305±158 9
Geppert and colleagues [72] 59 (35 to 85) SIRS 116.9±33.4 7 291±227.4 27
Leone and colleagues [76] 45 to 47 (16 to 21) SIRS 62±20 26 129±98 11
ACCP/SCCM, American college of chest physicians/society of critical care medicine; PRISM, pediatric risk of mortality; SIRS, systemic inflammatory response
syndrome; SNAP, score for neonatal acute physiology; SOFA, sequential organ failure assessment.
aData presented as mean (range) or mean ± standard deviation.
Ages expressed in years unless otherwise stated.
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tants, neonatal neutrophils exhibited a significantly
lower shedding response compared with adult neutro-
phils [42,43]. Austgulen and colleagues suggest that
t h e s ed i f f e r e n c e sm a yb ear e f l e c t i o no fad e v e l o p i n g
immune system [45] that shows features of hypore-
sponsiveness [46]. Since neonatal sepsis/infection is
particularly difficult to diagnose and no dependable
predictors exist, sE-selectin [45,47,48], sL-selectin [49,50]
and sP-selectin [48,49] as well as sICAM-1 [50-59] and
sVCAM-1 [49] were evaluated as markers for the presence
of infection in neonates. However, none of these soluble
isoforms were introduced in a clinical setting because they
did not reach predictive ability. The above discussion (and
additional elaborations below) points toward complexities
that need to be resolved before meaningful interpretations
can be made.
Children
Generally speaking, the basal levels of soluble adhesion
molecules in healthy children are similar to or lower
than those of adults and neonates. However, both the
relative amount and the absolute amount of sE-selectin
and sL-selectin during sepsis seem much higher, whereas
sP-selectin levels remain low. On the other hand,
sICAM-1 and sVCAM-1 have similar basal levels and
sepsis generates comparable or higher levels versus
adults (Tables 2, 3, 4, 5 and 6 and Figure 3). Three stud-
ies assessed age-dependent differences in levels of selec-
tins in healthy children [59,60,64]. Interestingly, infants
Table 5 Levels of soluble intercellular adhesion molecule-1 in neonates, children and adults
Study (reference) Mean age Sepsis criteria Healthy (μg/ml)
a Number
of patients
(healthy)
Sepsis (μg/ml)
a Number
of patients
(sepsis)
Neonates
Figueras-Aloy and colleagues [49] 0 to 14 days SNAP-II 215 (156 to 274) 12 426 (394 to 458) 15
Apostolou and colleagues [58] At term Clinical 358.4±28.9 10 710.7±56.6 10
Dollner and colleagues [52] 0 to 7 days Clinical 244 (95.2 to 500) 24 413 (255.6 to 500) 18
Austgulen and colleagues [45] Pre/at term Clinical 258.8 (94 to 500) 168 394.2 (197.5 to 500) 24
Berner and colleagues [51] 0 to 3 days Clinical 421 (291 to 459) 35 446 (171 to 534) 136
Edgar and colleagues [57] 0 to 7 days Clinical 165 (130 to 290) 27 341 (236 to 554) 192
Edgar and colleagues [56] 0 to 7 days Clinical 205 46 406 46
Children
Andrys and colleagues [60] 6 to 10 346.8 (206.8 to 486.8) 68
11 to 15 269 (184.1 to 354) 90
Paize and colleagues [61] 2 to 16 PRISM 260 (240 to 300) 40 705 (400 to 850) 20
Whalen and colleagues [63] 1 day to 17 years Criteria of Doughty
and colleagues
b
205±29 14 595 77
Nash and colleagues [64] 9 310 (280 to 410) 81
15 300 (270 to 390)
Briassoulis and colleagues [19] 6.5 (2.8) PRISM 199±98 10 172±93 10
Adults
Weigand and colleagues [66] 58.7 (4.4) ACCP/SCCM 190 7 1,100 14
Soderquist and colleagues [70] 71 (10 to 91) Unknown 202 (62 to 392) 15 451 (216 to 1,030) 41
Scherpereel and colleagues [77] 58.9 (14.9) SAPS II 2,130 63
Hofer and colleagues [78] 65.9 (12.4) APACHE II 219.6 (195.2 to 285.1) 108 444.7 (330 to 665.5) 18
De Pablo and colleagues [73] 61.2 (3.2) APACHE II 480 36 1100 52
Kayal and colleagues [74] 57.2 (3.9) ACCP/SCCM 208±20.5 9 868±131 25
Shapiro and colleagues [6] 57 (19) APACHE III 185 207 240 13
Andrys and colleagues [60] 46 140 (60.2 to 218.4) 68
Leone and colleagues [76] 45 to 47 (16 to 21) SIRS 151 26 824 11
ACCP/SCCM, American college of chest physicians/ society of critical care medicine; APACHE, acute physiology and chronic health evaluation; PRISM, pediatric risk
of mortality; SAPS, simplified acute physiology score; SIRS, systemic inflammatory response syndrome; SNAP, score for neonatal acute physiology.
aData presented
as mean (range) or mean ± standard deviation.
bCriteria from [75]. Ages expressed in years unless otherwise stated.
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pared with toddlers (average age 2 years) [59]. Addition-
ally, healthy children (age 9 to 15.5 years) were found to
have significantly decreasing sE-selectin levels with in-
creasing age [64]. The authors of all three studies suggest
that potential developmental changes exist in both expres-
sion and shedding of selectins, but that the physiological
relevance of these observations remains to be determined.
During sepsis in children, studies show a significant in-
crease in levels of soluble adhesion molecules [19,61-63].
Interestingly, Briassoulis and colleagues show significant
increase of sE-selectin, as well as sL-selectin and ICAM-1,
especially amongst survivors [19]. The authors conclude
that inadequate or suppressed shedding during sepsis
might be associated with increased mortality, and they
hypothesize that the shedding process is indeed protective
for the host. Similarly, in a large pediatric ICU study on
microcirculatory dysfunction in meningococcal sepsis in
children, levels of sE-selectin, sVCAM-1 and sICAM-1,
but not sP-selectin, were significantly increased in septic
patients but negatively correlated with the degree of
microcirculatory dysfunction (a measure of sepsis sever-
ity), as assessed by sublingual imaging [61].
Adults
Generally, basal levels of soluble adhesion molecules in
adults are similar to or somewhat lower than those of
neonates and children (Tables 2, 3, 4, 5 and 6 and
Figure 3). All molecules show increase during sepsis,
with sICAM-1 and sP-selectin exhibiting the greatest
increases compared with neonates and children. Age
group stratification in levels of soluble adhesion mol-
ecules in adults is limited. Rudloff and colleagues de-
termined sICAM-1 levels in healthy adults between
18 and 65 years old and reported no age-dependent
differences [79].
As discussed above, in a large number of clinical sepsis
studies in adults, higher levels of soluble adhesion molecules
were generally related to severity of disease and mortality, al-
though statistically significant correlations could not be
made [5,6,15-17,37,65-74,76-82]. Some studies imply an al-
ternate interpretation of these levels. For example, clinical
studies have demonstrated that septic adults with modest
levels of soluble adhesion molecules (putatively reflecting
inadequate/aberrant shedding) had poorer outcome
and higher mortality than those with the highest levels
[22,83]. Donnelly and colleagues found that critically
Table 6 Levels of soluble vascular cell adhesion molecule-1 in neonates, children and adults
Study (reference) Mean age Sepsis criteria Healthy (μg/ml)
a Number
of patients
(healthy)
Sepsis (μg/ml)
a Number
of patients
(sepsis)
Neonates
Figueras-Aloy and colleagues [49] 0 to 14 days SNAP-II 928 (856 to 1,005) 12 1,112 (1,072 to 1,153) 15
Austgulen and colleagues [45] 0 to 7 days Clinical 1,940 (1,100 to 3,500) 168 1,950 (1,190 to 3,495) 24
Children
Andrys and colleagues [60] 6 to 15 years 590.8 (359.6 to 822.0) 68
Paize and colleagues [61] 2.16 PRISM 600 (390 to 790) 40 1,550 (1,360 to 1,910) 20
Krueger and colleagues [62] 3.5 (0.2 to 16) ACCP/SCCM 766 (644 to 915) 22 1,239 (928 to 1,615) 22
Whalen and colleagues [63] 1 day to 17 years Criteria of Doughty
and colleagues
b
231± 46 14 600 77
Nash and colleagues [64] 9 years 790 (580 to 1,060) 81
15 years 780 (420 to 1,000)
Adults
Presterl and colleagues [65] 51 APACHE II 545 (374 to 829) 20 2633 20
Knapp and colleagues [68] 51 to 55 (21 to 96) APACHE III 569± 98 15 1,395±801 28
Soderquist and colleagues [70] 71 (10 to 91) Unknown 533 (354 to 1,018) 15 1,173 (525 to 3,500) 41
Hofer and colleagues [78] 65.9 (12.4) APACHE II 1,524.7 (991.2
to 2,038)
108 1,147.9 (883.5 to
2,074.4)
18
De Pablo and colleagues [73] 61.2 (3.2) APACHE II 890 48 1,600 52
Shapiro and colleagues [6] 57 (19) APACHE III 1,050 49 1,550 95
Andrys and colleagues [60] 46 743 (338 to 1,148) 68
Leone and colleagues [76] 45 to 47 (16 to 21) SIRS 458± 123 26 1,604±940 11
ACCP/SCCM, American college of chest physicians/ society of critical care medicine; APACHE, acute physiology and chronic health evaluation; PRISM, pediatric risk
of mortality; SIRS, systemic inflammatory response syndrome; SNAP, score for neonatal acute physiology.
aData presented as mean (range) or mean ± standard
deviation.
bCriteria from [75]. Ages expressed in years unless otherwise stated.
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chance of developing adult respiratory distress syn-
drome [83], and Seidelin and colleagues found that
worse outcomes in septic patients correlated with lesser
increases in sL-selectin levels [22]. Interestingly, one ex-
perimental study found significantly decreased leukocyte–
endothelial interaction in a murine cecal ligation model of
sepsis upon addition of exogenous sL-selectin into the cir-
culation at levels comparable with those found in septic
adults [27].
Adhesion molecule sheddases in sepsis: a delicate
balance
The levels of adhesion molecules are an indirect result
of protein cellular expression levels and a direct result of
the proteolytic activity of sheddases. Thus, as discussed
above (for example, see [42-44]), expression and shed-
ding activities can both independently contribute to
overall levels of soluble adhesion molecules in circula-
tion. Several studies have independently assessed levels
of circulating sheddases and sheddase antagonists (that
is, tissue inhibitor metalloproteinases) in clinical and ex-
perimental sepsis in efforts to clarify their contribution
to pathology. However, so far these have yielded diverse
and inconsistent results showing varied correlation of
levels with protection and pathology [84-88], suggesting
a delicate balance is required.
The sensitive relationship between levels/activity of
sheddases and outcome/effects in the host during sepsis
is best reflected by studies from Long and colleagues in-
vestigating the role of ADAM-17 in L-selectin shedding
in murine sepsis [12,89]. They found that ADAM-17 in
mice acts as a homeostatic (rheostat) molecule to con-
trol their neutrophil infiltration at sites of inflammation
by regulating surface density of L-selectin. Low ADAM-
17 activity results in little L-selectin shedding and too
much neutrophil infiltration with subsequent collateral
tissue damage. However, excessive activity of ADAM-17
promotes excessive L-selectin shedding and subse-
quently impairs neutrophil infiltration, which is needed
to clear inflammation and infection.
Finally, evidence of age-related changes in sheddases
and sheddase antagonists (that is, tissue inhibitor
Healthy Neonates
Septic Neonates
Healthy Children
Septic Children
Healthy Adults
Septic Adults
A
B
C
D
E
sL-selectin (ug/mL)
sP-selectin (ug/mL)
sE-selectin (ug/mL)
1000
2000
3000
4000
6000
6500
0
100
200
300
400
500
0
0
0
0
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200
300
sICAM 1(ug/mL)
sVCAM 1(ug/mL)
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2000
3000
250
500
750
1000
2000
2500
1250
Figure 3 Levels of soluble E-selectin, L-selectin and P-selectin,
intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1 in healthy and septic neonates, children and adults.
Values of soluble adhesion molecules assessed in diverse clinical
studies (see Tables 2, 3, 4, 5 and 6) plotted by adhesion molecule to
graphically compare absolute and relative amounts in both healthy
and septic subjects in distinct age groups. (A) Soluble L-selectin
(sL-selectin). (B) Soluble P-selectin (sP-selectin). (C) Soluble E-
selectin (sE-selectin). (D) Soluble intercellular adhesion molecule-1
(sICAM-1). (E) Soluble vascular cell adhesion molecule-1 (sVCAM-1).
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ing to speculate that these differences could partially
underlie the observed age-related discrepancies in
levels of soluble adhesion molecules [90,91].
Conclusion
Increased levels of soluble adhesion molecules generally
correlate well with the presence of sepsis in neonates,
children and adults. However, their levels are still poorly
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Figure 4 Changes in cell surface and circulating soluble adhesion molecules during progression of inflammatory responses. (A)
Idealized homeostatic inflammatory response. Schematic showing the hypothetical increase in cell surface adhesion molecules (blue line)
associated with onset of inflammation and the subsequent decrease in them during resolution of inflammation. Shedding and accumulation of
circulating soluble adhesion molecules similarly rise and fall (green line), but with a lag in time. Points of highest levels of cell surface adhesion
molecules (and not necessarily soluble adhesion molecules) should correlate with the greatest levels of overall inflammation and a propensity for
collateral tissue damage (red shading). (B) Exaggerated inflammatory and response. Schematic as in (A) illustrating a more severe inflammation
and greater initial cell surface adhesion molecule expression, and subsequently greater levels of soluble adhesion molecule production. (C)
Aberrant shedding and sustained inflammation. Schematic as in (A) illustrating how a hypothetical deficiency in shedding during inflammation
could lead to low levels of soluble adhesion molecules, leaving cell surface adhesion molecules elevated, and allowing for heightened and
sustained inflammation.
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Our review raises important issues that need further atten-
tion, including age-related discrepancies in soluble adhesion
molecule levels and even basic questions about whether
these should correlate positively or negatively with mortality.
First, there is a well-articulated hypothesis (and significant
experimental support) that shedding is indeed principally a
homeostatic process that works to reduce inflammation and
promote resolution of inflammation (Figure 4). This is
thought to act at two complementary levels: removal of ad-
hesion molecules from cell surfaces directly reduces the abil-
ity for cell–cell interaction; and the resulting soluble
isoforms serve as competitive antagonists (or decoy ligands)
for the remaining cell surface adhesion molecules.
Second, there is substantial evidence that disruption of
shedding during sepsis, resulting in substantially lower
levels of soluble adhesion molecules (that is, retention of
elevated cell surface adhesion molecule levels), could
lead to exacerbation of inflammation or promotion of
mortality (Figure 4C). Thus, as illustrated in Figure 4,
there are many points during the progression of an in-
flammatory response whereby the functional significance
(with respect to the severity of the underlying inflamma-
tion) of a given level of soluble adhesion molecule varies
greatly. In addition, levels of sheddases are also altered
in human and experimental sepsis, suggesting putative
functional contribution for these changes in regulating
disease progression. The interaction of adhesion mole-
cules and sheddases in the dynamic microenvironment
of the cellular surfaces implicates a strong interdepend-
ence of these molecules. However, to our knowledge, no
studies exist that combine the assessment of both adhe-
sion molecules and their sheddases to assess clinical out-
come. Thus, a novel and potentially critical opportunity
to enhance clinical efficacy of soluble adhesion mole-
cules exists that remains untapped. Such a combinatorial
approach might be particularly useful for improving both
sepsis diagnosis (which is greatly needed for the challen-
ging situations in the febrile neonate or extreme older
person) and our ability to track efficacy of therapies.
Furthermore, serial assessment of the combination of
these markers might even be effective in determining
morbidity or mortality risk. Finally, it is interesting to con-
sider whether regulation of sheddases and adhesion mole-
cules might be regulated in sepsis at the epigenetic level,
potentially offering additional ways to assess disease sever-
ity and predict outcomes [92].
Additionally, the age-related and comorbidity-related het-
erogeneity in levels of soluble adhesion molecules, as well as
sheddases, in healthy individuals and septic patients could
be an expression of a different basal state, as well as different
responsiveness in sepsis, potentially leading to discrepancies
in pathophysiology and disease progression between neo-
nates, children or adults. Interestingly, epidemiological
research shows a biphasic pattern in age-related differ-
ences in incidence and mortality [2-4]. The incidence
of neonatal sepsis is 1 to 8 per 1,000 live births with
mortality rates of 16%. These rates decrease during
childhood (0.2/1,000 children, mortality 10%) and then
increase in adults (26.2/1,000 in those over 85 years
old, mortality 38.4%) [2-4]. A direct correlation be-
tween these rates and levels of soluble adhesion mole-
cules remains speculative, but further attention to this
could provide new insights.
In conclusion, while predictive properties of soluble ad-
hesion molecules have been researched intensively, their
levels are still poorly predictive of sepsis outcome and mor-
tality. We propose two novel directions for improving clin-
ical utility of soluble adhesion molecules: the combined
simultaneous analysis of levels of adhesion molecules and
their sheddases; and taking age-related discrepancies into
account. Additional investigation of these issues may pro-
vide better understanding of the pathophysiology of sepsis
and increased usefulness of soluble adhesion molecules as
diagnostic and predictive biomarkers.
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